Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

491
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
491
Amyloid Fibrils03:03

Amyloid Fibrils

9.6K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.6K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

553
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
553

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lymphodepleting chemotherapy potentiates neoantigen-directed T cell therapy by enhancing antigen presentation.

Cell reports. Medicine·2025
Same author

Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer.

Cancer discovery·2025
Same author

Altered Lipid Metabolism in CNS Demyelination and Remyelination Are Key Elements Driving Progressive MS.

International journal of molecular sciences·2025
Same author

MIF functional polymorphisms are associated with acute GVHD progression and steroid-refractoriness.

Frontiers in immunology·2025
Same author

Translation dysregulation in cancer as a source for targetable antigens.

Cancer cell·2025
Same author

The CD74 inhibitor DRhQ improves short-term memory and mitochondrial function in 5xFAD mouse model of Aβ accumulation.

Metabolic brain disease·2025
Same journal

Targeting the cGAS-STING pathway alleviates neuroinflammation and cognitive impairment induced by chronic infection of Toxoplasma gondii.

Journal of neuroinflammation·2026
Same journal

Dysregulated glia and periglomerular cells in the olfactory bulb and altered lipocalins in the olfactory epithelium underlie olfactory dysfunction in a murine model of eosinophilic chronic rhinosinusitis.

Journal of neuroinflammation·2026
Same journal

Human umbilical cord blood mononuclear cells ameliorate vascular dementia by modulating microglial myelin debris handling and white matter injury.

Journal of neuroinflammation·2026
Same journal

Neuron-specific deletion of ADAR1 induces brain malformation and early postnatal lethality.

Journal of neuroinflammation·2026
Same journal

Regional mapping of CSF1R-positive microglia in neurodegenerative diseases and progressive MS, with exploratory presynaptic marker analyses.

Journal of neuroinflammation·2026
Same journal

Microglial checkpoint collapse in Alzheimer's disease: a tri-axial framework for biomarker-informed neuroimmune therapy.

Journal of neuroinflammation·2026
See all related articles

Related Experiment Video

Updated: Jul 6, 2025

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases
09:33

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases

Published on: July 28, 2013

28.5K

MIF contribution to progressive brain diseases.

Agata Matejuk1, Gil Benedek2, Richard Bucala3

  • 1Department of Immunology, Collegium Medicum, University of Zielona Góra, Zielona Góra, Poland. a.matejuk@cm.uz.zgora.pl.

Journal of Neuroinflammation
|January 4, 2024
PubMed
Summary
This summary is machine-generated.

Chronic inflammation underlies progressive brain diseases. Macrophage migration inhibitory factor (MIF) is a key inflammatory mediator and potential therapeutic target for neurological conditions like Alzheimer's and MS.

Keywords:
ADAstrocytomaMIFMSNeurodegenerationNeuroinflammation

More Related Videos

Assessing Changes in Synaptic Plasticity Using an Awake Closed-Head Injury Model of Mild Traumatic Brain Injury
09:49

Assessing Changes in Synaptic Plasticity Using an Awake Closed-Head Injury Model of Mild Traumatic Brain Injury

Published on: January 20, 2023

3.2K
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

4.7K

Related Experiment Videos

Last Updated: Jul 6, 2025

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases
09:33

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases

Published on: July 28, 2013

28.5K
Assessing Changes in Synaptic Plasticity Using an Awake Closed-Head Injury Model of Mild Traumatic Brain Injury
09:49

Assessing Changes in Synaptic Plasticity Using an Awake Closed-Head Injury Model of Mild Traumatic Brain Injury

Published on: January 20, 2023

3.2K
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

4.7K

Area of Science:

  • Neuroscience
  • Immunology
  • Pathology

Background:

  • Progressive brain diseases pose significant societal and economic burdens, necessitating novel therapeutic strategies.
  • Chronic, unresolved inflammation is a common pathological basis for many progressive brain malfunctions.
  • Macrophage migration inhibitory factor (MIF) is an inflammatory mediator with diverse roles in the central nervous system (CNS), including development and neuroinflammation.

Purpose of the Study:

  • To review the critical role of Macrophage Migration Inhibitory Factor (MIF) in the pathogenesis of major neurological diseases.
  • To highlight MIF as a potential biomarker and therapeutic target for CNS disorders.

Main Methods:

  • This review synthesizes current research on MIF's involvement in neurological diseases.
  • Focus is placed on its function in neuroinflammation and disease progression.

Main Results:

  • MIF plays a significant role in the neuroinflammatory processes underlying multiple sclerosis (MS), Alzheimer's disease (AD), and glioblastoma (GBM).
  • Its multifaceted actions in the CNS make it a promising candidate for therapeutic intervention.

Conclusions:

  • MIF is a crucial factor in the development and progression of various neurological diseases.
  • Targeting MIF offers a promising avenue for developing new treatments for debilitating brain conditions.